Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Regulus Therapeutics Inc RGLS

Healthcare Biotechnology
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RGLS)

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

PR Newswire March 21, 2024

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

PR Newswire March 12, 2024

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire March 12, 2024

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire January 2, 2024

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

PR Newswire November 22, 2023

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

PR Newswire November 9, 2023

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire November 2, 2023

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire October 19, 2023

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire September 20, 2023
View More News ››

Opinion & Analysis (NDAQ:RGLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RGLS)

RGLS ..... LMFAO ....right again ; )

N>H>O>D I sold too early..... All is good !
Iseneschal - September 12, 2022

RGLS ....move your $'s into.....

ACOR.... HSDT ; )  JMHO
Iseneschal - September 12, 2022

RGLS ..... I love money !

Sold all into the vol spike ...who knows what tomorrow may bring.  Have to bank when it's staring tou in the face   ...
Iseneschal - September 12, 2022

RGLS ..... A break of $2.45 will be meaningful

Cheers  The volume spiked as previously predicted ; )
Iseneschal - September 12, 2022

RGLS ..... N.H.O.D ; )

Now for a huge volume increase to vault this into the stratosphere ; ) JMHO
Iseneschal - September 12, 2022

RGLS....volume and Price Action ; )

JUst tapping the RBL as I write this....could be a small PB No guts ....no glory Wait for it  ; ) JMHO
Iseneschal - September 12, 2022
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »